Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells

Prostate

Volumn 68, Issue 14, 2008, Pages 1531-1545

  Bindukumar, B ^a,b   Schwartz, Stanley ^b   Aalinkeel, Ravikumar ^b   Mahajan, Supriya ^b   Lieberman, Alicia ^a   Chadha, Kailash ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

DIGE; MetaCore; PC 3M cells; Prostate cancer; Prostate specific antigen; Proteomic analysis

Indexed keywords

DJ 1 PROTEIN; GENE PRODUCT; HEAT SHOCK PROTEIN 60; ISOPROTEIN; LAMININ RECEPTOR; PROSTATE SPECIFIC ANTIGEN; VIMENTIN; FLUORESCENT DYE; RNA; TUMOR PROTEIN;

ARTICLE; CANCER CELL; COMPUTER PROGRAM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MASS SPECTROMETRY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMAGE PROCESSING; MALE; METABOLISM; METHODOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 51649123008     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20811     Document Type: Article

References (75)

1. Stenman U, Finne P, Zhang W, Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology 2000;56(6):893-898.
2. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: Update 1994. J Urol 1994;152(5 Pt 1):1358-1368.
3. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76(5):1899-1903.
4. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78(6):1536-1539.
5. Yu H, Diamandis EP. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995;153(3 Pt 2):1004-1008.
6. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41(1):54-58.
7. Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27(2):75-79.
8. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. Clin Cancer Res 1998;4(6):1489-1497.
9. Levesque M, Hu H, D'Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995;9(2):123-128.
10. Kucera E, Kainz C, Tempfer C, Zeillinger R, Koelbl H, Sliutz G. Prostate specific antigen (PSA) in breast and ovarian cancer. Anticancer Res 1997;17(6D):4735-4737.
11. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells 1. AACR 2002;62:3498-3502.
12. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75(4):1046-1053.
13. Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 1998;18(11):6711-6718.
14. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91(19):1635-1640.
15. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, Nelson BJ. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003;56(3):212-219.
16. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005;7(3):241-252.
17. Aebersold R, Rist B, Gygi SP. Quantitative proteome analysis: Methods and applications. Ann N Y Acad Sci 2000;919:33-47.
18. Harry JL, Wilkins MR, Herbert BR, Packer NH, Gooley AA, Williams KL. Proteomics: Capacity versus utility. Electrophoresis 2000;21(6):1071-1081.
19. Tonella L, Walsh BJ, Sanchez JC, Ou K, Wilkins MR, Tyler M, Frutiger S, Gooley AA, Pescaru I, Appel RD, Yan JX, Bairoch A, Hoogland C, Morch FS, Hughes GJ, Williams KL, Hochstrasser DF. 98 Escherichia coli SWISS-2DPAGE database update. Electrophoresis 1998;19(11):1960-1971.
20. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405(6788):837-846.
21. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2(9):1627-1636.
22. Bindukumar B, Kawinski E, Cherrin C, Gambino LM, Nair MP, Schwartz SA, Chadha KC. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813(1-2):113-120.
23. Kawinski E, Levine E, Chadha K. Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate 2002;50(3):145-153.
24. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57(21):4924-4930.
25. Wessel D, Flugge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984;138(1):141-143.
26. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1(3):377-396.
27. Breci L, Hattrup E, Keeler M, Letarte J, Johnson R, Haynes PA. Comprehensive proteomics in yeast using chromatographic fractionation, gas phase fractionation, protein gel electrophoresis, and isoelectric focusing. Proteomics 2005;5(8):2018-2028.
28. Medina ML, Haynes PA, Breci L, Francisco WA. Analysis of secreted proteins from Aspergillus flavus. Proteomics 2005;5(12):3153-3161.
29. Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M. Femtomole sequencing of proteins from Polyacrylamide gels by nano-electrospray mass spectrometry. Nature 1996;379(6564):466-469.
30. Haynes PA, Gygi SP, Figeys D, Aebersold R. Proteome analysis: Biological assay or data archive? Electrophoresis 1998;19(11):1862-1871.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156-159.
32. Qi C, Zhu YT, Chang J, Yeldandi AV, Rao MS, Zhu YJ. Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2. Biochem Biophys Res Commun 2005;328(2):393-398.
33. Huszar M, Halkin H, Herczeg E, Bubis J, Geiger B. Use of antibodies to intermediate filaments in the diagnosis of metastatic amelanotic malignant melanoma. Hum Pathol 1983;14(11):1006-1008.
34. Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valvenus E, Clark R, McCormick F, Stampfer M, Abularach S, Gelmann EP. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res 1989;49(15):4258-4263.
35. Cappello F, Bellafiore M, Palma A, David S, Marciano V, Bartolotta T, Sciume C, Modica G, Farina F, Zummo G, Bucchieri F. 60KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis. Eur J Histochem 2003;47(2):105-110.
36. Waltregny D, de Levai L, Coppens L, Youssef E, de Leval J, Castronovo V. Detection of the 67-kD laminin receptor in prostate cancer biopsies as a predictor of recurrence after radical prostatectomy. Eur Urol 2001;40(5):495-503.
37. Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 2007;67(10):4630-4637.
38. Chen SL, Zhang XK, Halverson DO, Byeon MK, Schweinfest CW, Ferris DK, Bhat NK. Characterization of human N8 protein. Oncogene 1997;15(21):2577-2588.
39. Malinda KM, Kleinman HK. The laminins. Int J Biochem Cell Biol 1996;28(9):957-959.
40. Malinda KM, Nomizu M, Chung M, Delgado M, Kuratomi Y, Yamada Y, Kleinman HK, Ponce ML. Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. Faseb J 1999;13(1)53-62.
41. Aznavoorian S, Stracke ML, Krutzsch H, Schiffmann E, Liotta LA. Signal transduction for Chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 1990;110(4):1427-1438.
42. Kibbey MC, Grant DS, Kleinman HK. Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: An in vivo Matrigel model. J Natl Cancer Inst 1992;84(21):1633-1638.
43. Menard S, Castronovo V, Tagliabue E, Sobel ME. New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 1997;67(2):155-165.
44. Pupa SM, Menard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192(3):259-267.
45. Reich R, Blumenthal M, Liscovitch M. Role of phospholipase D in laminin-induced production of gelatinase A (MMP-2) in metastatic cells. Clin Exp Metastasis 1995;13(2):134-140.
46. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 2002;52(4):255-264.
47. Menard S, Tagliabue E. Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 1998;52(1-3):137-145.
48. Satoh K, Narumi K, Abe T, Sakai T, Kikuchi T, Tanaka M, Shimo-Oka T, Uchida M, Tezuka F, Isemura M, Nukiwa T. Diminution of 37-kDa Jaminin binding protein expression reduces tumour formation of murine lung cancer cells. Br J Cancer 1999;80(8):1115-1122.
49. Waltregny D, de Levai L, Menard S, de Leval J, Castronovo V. Independent prognostic value of the 67-kd laminin receptor in human prostate cancer. J Natl Cancer Inst 1997;89(16):1224-1227.
50. Osborn M, Weber K. Intermediate filaments: Cell-type-specific markers in differentiation and pathology. Cell 1982;31(2 Pt 1):303-306.
51. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 1987;47(1):281-286.
52. Mitchell S, Abel P, Ware M, Stamp G, Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 2000;85(7):932-944.
53. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, Bray MR, Liu FF, Tsao MS, Mak TW. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005;7(3):263-273.
54. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: Identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 2003;63(20):6928-6934.
55. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004;5(2):213-218.
56. Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA. The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc Natl Acad Sci U S A 2003;100(16):9256-9261.
57. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004;2(11):e362.
58. Frydman J, Hartl FU. Principles of chaperone-assisted protein folding: Differences between in vitro and in vivo mechanisms. Science 1996;272(5267):1497-1502.
59. Cappello F, Bellafiore M, Palma A, Marciano V, Martorana G, Belfiore P, Martorana A, Farina F, Zummo G, Bucchieri F. Expression of 60-kD heat shock protein increases during carcinogenesis in the uterine exocervix. Pathobiology 2002;70(2):83-88.
60. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989;56(3):379-390.
61. Tanaka M, Sasaki H, Kino I, Sugimura T, Terada M. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res 1992;52(12):3372-3377.
62. Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996;178(1):48-52.
63. Shields LB, Gercel-Taylor C, Yashar CM, Wan TC, Katsanis WA, Spinnato JA, Taylor DD. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig 1997;4(6):298-304.
64. Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999;39(4):298-304.
65. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S, Balmain A. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003;34(4):403-412.
66. Balleine RL, Fejzo MS, Sathasivam P, Basset P, Clarke CL, Byrne JA. The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer 2000;29(1):48-57.
67. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R, Wang PH. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol 2003;35(9):1135-1143.
68. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005;309(5741):1732-1735.
69. Charette SJ, Landry J. The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis. Ann N Y Acad Sci 2000;926:126-131.
70. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004;103(4):1464-1471.
71. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A 2005;102(27):9691-9696.
72. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005;37(6):579-583.
73. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9(2):166-180.
74. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6(1):160-165.
75. Fang P, Hwa V, Little BM, Rosenfeld RG. IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis. Growth Horm IGF Res 2008;18(1):38-46.